|1.||Stocker, Roland: 9 articles (03/2012 - 08/2002)|
|2.||Tardif, Jean-Claude: 8 articles (05/2006 - 01/2002)|
|3.||Litvin, A A: 7 articles (11/2011 - 01/2006)|
|4.||Wu, Ben J: 6 articles (03/2012 - 09/2004)|
|5.||Yamashita, Shizuya: 5 articles (08/2015 - 11/2005)|
|6.||Liu, Tong: 5 articles (02/2015 - 02/2009)|
|7.||Farina, Marcelo: 5 articles (04/2013 - 03/2012)|
|8.||Singal, P K: 5 articles (04/2005 - 04/2000)|
|9.||Li, Guangping: 4 articles (02/2015 - 02/2009)|
|10.||Fan, Jianglin: 4 articles (01/2015 - 01/2013)|
09/06/1996 - "The results demonstrate that although probucol provided a significant protection against Cu(2+)-induced oxidative modification of LDL, it lacked effect on the development of femoral atherosclerosis. "
02/01/1992 - "Thus, probucol was effective in preventing atherosclerosis in long-term studies at both early and late stages."
02/01/1992 - "In the second study (study B), administration of probucol was commenced with 8-month-old WHHL rabbits to investigate whether the drug was effective for limiting atherosclerosis in rabbits in which plaques had already developed. "
01/01/2000 - "Protective effects of probucol in two animal models of atherosclerosis."
02/01/2013 - "Probucol, an antioxidant and anti-inflammatory agent counteracting atherosclerosis and restenosis, is partially effective by influencing suicidal cell death or apoptosis. "
12/01/1997 - "Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL-C levels."
05/01/2002 - "Probucol is also used for hypercholesterolemia and recently is known that it prevent the restenosis of the coronary artery after PTCA. "
07/01/1999 - "They also suggest that the reduction of hypercholesterolemia after the change in diet or treatment with probucol suppressed glomerular injury by suppressing the glomerular MCP-1 expression. "
01/01/1998 - "Evaluation of effectiveness of hypolipidemic action of probucol in doses 500 and 1000 mg/day and comparison of probucol blood concentrations on the treatment month 3 and 6. Probucol (Akrikhin, Russia) was given to 41 patients with primary hypercholesterolemia in a dose 500 mg/day. "
10/01/1997 - "Probucol is used to treat hypercholesterolemia and also has an anti-atherogenic effect. "
06/01/1994 - "The study suggests potential usefulness of antioxidant (probucol) therapy in ADR cardiomyopathy."
11/01/2003 - "Probucol has been reported to completely prevent DOX-induced cardiomyopathy. "
06/01/2000 - "An increase in oxidative stress, GSHPx inactivation and MnSOD downregulation during ADR cardiomyopathy were prevented by probucol treatment."
06/01/2000 - "Probucol has been reported to completely prevent ADR cardiomyopathy without interfering with its antitumor effects. "
10/01/2009 - "Attention should be drawn to probucol, a lipid-lowering agent with potent antioxidant properties, which provides complete protection against Dox-induced cardiomyopathy in rats without interfering with the antitumor properties of Dox in an experimental setting. "
02/28/2002 - "A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. "
12/01/1996 - "These structural changes within the GBM could be of functional relevance because treatment with the potent LPO-antagonist probucol reduces proteinuria by < 80%. "
10/01/1994 - "The close temporal correlation of the occurrence of LPO with proteinuria and the ability of probucol to inhibit proteinuria support a causal role for LPO in the the alteration of the glomerular permselectivity which results in proteinuria."
10/01/1994 - "When LPO was inhibited by pretreatment of PHN rats with the antioxidant probucol, proteinuria was reduced by approximately 85%, and glomerular immunostaining for dialdehyde adducts was markedly reduced, even though the formation of immune deposits was not affected. "
03/01/2006 - "In conclusion, our study provides the first evidence that the antioxidant probucol, when added to an Ang II receptor blockade, fully arrests proteinuria and disease progression in GN. "
04/01/1992 - "This effect implies that probucol can be effective for treatment of atheromatous lesions, because xanthoma is a lesion which consists of macrophage-derived foam cells. "
05/01/2013 - "Plane xanthoma is primarily treated with excisional or abrasive therapies; however, probucol can be a safe and effective alternative therapy for DNPX."
05/01/2013 - "Successful treatment of diffuse normolipemic plane xanthoma with probucol."
04/01/1992 - "However, the precise mechanism of probucol in causing regression of xanthoma has not been clarified. "
03/01/1990 - "Moreover, there are some clinical reports that probucol causes a regression of cutaneous and tendon xanthomas in homozygous FH patients. "
|2.||Angioplasty (Angioplasty, Transluminal)